Pinned
The very nature of extraordinary is to deviate from normative.
Elli Papaemmanuil, PhD
952 posts
Elli Papaemmanuil, PhD
@PapaemmanuilLab
Computational Oncology. Explores 🧬 tech, algorithms & data to improve treatment decisions in oncology. Opinions my own. ICR - Sanger - MSKCC / Isabl.io
- Most cancers have multiple mutations. In unison these define tumor biology, response to Rx & outcomes. Yet model systems & correlative studies focus on single biomarkers.We need clinical decision support tools that account for this heterogeneity. A 🧵 on our recent AML study👇
- I speak in an accent in all three languages that I speak...including Greek. Your accent is your story and it is your journey that informs what you talk about and how you talk about it. That’s what matters. Supporting #diversity in #science and #tech.
- What is the risk conferred by my disease? One of the hardest questions to answer in medicine. A on the development of the International Prognostic Scoring System Molecular in MDS published today
- 4months since publication (bit.ly/3aNEU64), >5K unique users from 65 countries have used the IPSS-M model (mds-risk-model.com) to compute risk for 42,500 patient profiles. High IF journal editor said "not ready for prime time". This is my type of impact factor.
- Is clinical reporting of acquired gene mutations as present or absent enough to inform cancer diagnosis, risk prognostication and treatment decisions? A thread on our paper published in @NatureMedicine today: go.nature.com/3i12ACk & commentary go.nature.com/3foWxpt
- Study of 570 cancer patients demonstrating clinical utility of whole genome and transcriptome sequencing in advanced metastatic disease. Actionable clinical findings in 83%. annalsofoncology.org/article/S0923-…
- It is clear. If there is one thing we owe to patients, hemato-oncologists, pathologists, clinical trialists, scientists & regulators is to unify the CAC/ICC & WHO classification ASAP. Why wait for the next revision? #ASH22 inspiration
- How do environmental exposures shape the fitness of somatic mutations during cancer development? Could we use this information to identify risk factors and develop preventative strategies? Our clonal hematopoiesis study go.nature.com/3dWboIZ published in @NatureGenet today /1
- Feasibility of clinical whole genome and transcriptome sequencing (WGTS) in oncology. A 🧵 on our latest study published in Nature Communications today:rdcu.be/cNOyQ
- Last time I left Europe I thought I would be back in a matter of weeks. Its been 30 months. Coming back, makes me realize how much I have missed It. The people, architecture, the hidden history in every corner, the pace of life & how accessible to most, quality of life is here💙
- Thrilled to share a preprint of our Clonal Hematopoiesis study in 24K cancer pts profiled by #MSKimpact @sloan_kettering showing how therapy, age+smoking shape the fitness of distinct CH mutations with implications for management+prevention of tMN risk bit.ly/34acSJL
- In our lab every day is a world cancer day 🇺🇸🇹🇷🇵🇱🇪🇸🇳🇪🇮🇷🇫🇷🇷🇺🇨🇦🇨🇴🇿🇦🇯🇲🇨🇳🇲🇦🇮🇪🇳🇴🇸🇪🇮🇹🇬🇷🇮🇱🏳️🌈🚩 celebrating diversity, learning about cancer.
- Fascinating new data on the significance of TP53 allelic state on genome stability and clinical outcomes in MDS (n>4,000). High risk disease disease presentation is specific to bi-allelic TP53 but not mono allelic events (33% of TP53) bit.ly/TP53MDS
